Key Developments: UMN Pharma Inc (4585.T)

4585.T on Tokyo Stock Exchange

3,100JPY
24 Oct 2014
Price Change (% chg)

¥10 (+0.32%)
Prev Close
¥3,090
Open
¥3,115
Day's High
¥3,230
Day's Low
¥3,100
Volume
99,300
Avg. Vol
153,529
52-wk High
¥4,330
52-wk Low
¥2,020

Search Stocks

Latest Key Developments (Source: Significant Developments)

UMN Pharma Inc updates new share issuance through private placement
Friday, 10 Oct 2014 03:20am EDT 

UMN Pharma Inc:To issue 123,100 new shares at price of 3,150 yen per share with amount of 387,765,000 yen through private placement to SMBC Nikko Securities Inc.Says subscription date on Oct. 15 and payment date on Oct. 16.Proceeds to be used for capital investment funds and loan repayment.  Full Article

UMN Pharma Inc announces share price
Wednesday, 10 Sep 2014 03:30am EDT 

UMN Pharma Inc:To issue 967,000 new shares through public offering at the price of 3,150 yen per share (3,046,050,000 yen in total).Subscription period from Sep. 11 to Sep. 12 and payment date on Sep. 18.To issue 144,000 new shares through private placement to SMBC Nikko Securities Inc at the price of 3,150 yen per share to raise up to 453,600,000 yen in total.Subscription date on Oct. 15 and payment date on Oct. 16.  Full Article

UMN Pharma Inc to issue new shares
Tuesday, 2 Sep 2014 02:30am EDT 

UMN Pharma Inc:To issue 967,000 new shares through public offering.Payment date is one day during Sep. 18 to Sep. 24.To issue 144,000 new shares through private placement to SMBC Nikko Securities Inc.Subscription date is one day during Oct. 15 to Oct. 21 and payment date is one day during Oct. 16 to Oct. 22.Proceeds to be used for investment in subsidiary and in research and development.  Full Article

UMN Pharma Inc amends consolidated mid-year outlook for FY 2014
Tuesday, 22 Jul 2014 04:25am EDT 

UMN Pharma Inc:Says the company lowered the consolidated mid-year outlook for revenue to 1,078 million yen from 1,105 million yen for FY ending Dec. 2014.Operating profit forecast increased to a loss of 1,796 million yen from a loss of 2,167 million yen.Ordinary profit forecast increased to a loss of 1,967 million yen from a loss of 2,292 million yen.Net profit forecast increased to a loss of 1,677 million yen from a loss of 2,079 million yen.Earnings per share increased to a loss of 198.63 yen from a loss of 246.74 yen.Comments the decreased research and development fund is the main reason for the forecast.  Full Article

UMN Pharma Inc signs syndicated loan contracts
Monday, 31 Mar 2014 02:00am EDT 

UMN Pharma Inc:Signed a syndicated loan contract for 1,500 million yen, with Sumitomo Mitsui Banking Corporation as the agent, on March 31.Says the valid period is from March 31 to Dec. 30.  Full Article

UMN Pharma Inc's subsidiary receives subsidy
Friday, 14 Feb 2014 01:00am EST 

UMN Pharma Inc:Says its subsidiary has received a subsidy of 2,213,799,000 yen from Ministry of Economy, Trade and Industry.  Full Article

UMN Pharma Inc signs joint research contract with Daiichi Sankyo Company, Limited
Friday, 14 Feb 2014 01:00am EST 

UMN Pharma Inc:Says it has signed a joint research contract with Daiichi Sankyo Company, Limited, regarding research and development of norovirus vaccine.  Full Article

UMN Pharma Inc and Astellas Pharma Inc announces summary results in phase III clinical trials of seasonal flu vaccine ASP7374
Wednesday, 15 Jan 2014 01:30am EST 

UMN Pharma Inc and Astellas Pharma Inc:Says the summary results for two Phase III clinical trials of the recombinant seasonal influenza HA vaccine ASP7374.Says one of these clinical trials enrolled 900 healthy volunteers aged from 20 to 64 years to compare the immunogenicity and safety of subcutaneously-administered ASP7374 with approved egg-derived trivalent inactivated vaccine as well as non-inferiority of ASP7374 to the egg-derived vaccine.Says this clinical trial showed non-inferiority of the recombinant seasonal influenza HA vaccine ASP7374 in comparison with the egg-based vaccine in terms of immunogenicity, and no major safety problem was observed in ASP7374.Says another clinical trial enrolled 55 healthy volunteers aged 61 and over to evaluate the immunogenicity and safety of intramuscularly-administered ASP7374.Says this clinical trial showed favorable immunogenicity with no major safety problem observed in ASP7374.  Full Article

UMN Pharma Inc lowers consolidated full-year outlook for FY 2013
Friday, 27 Dec 2013 04:00am EST 

UMN Pharma Inc:Sees consolidated full-year revenue of 93 million yen from 2,000 million yen for fiscal year 2013.Sees operating profit of a loss of 4,606 million yen from 1,900 million yen.Sees ordinary profit of a loss of 4,331 million yen from a loss of 2,100 million yen.Sees net profit of a loss of 3,894 million yen from a loss of 2,000 million yen.Sees earning per share of a loss of 515.02 yen from a loss of 277.58 yen.Says the negative outlook is due to the decreased sales and the increased cost.  Full Article

UMN Pharma Inc signs cooperation agreement with API Co., Ltd. and Yakult Honsha Co Ltd
Monday, 16 Dec 2013 09:30pm EST 

UMN Pharma Inc and Yakult Honsha Co Ltd:Says the two companies and API Co., Ltd. signed cooperation agreement on Dec. 17.Says the three companies will cooperate in research, development, production and sale of antibody biosimilar products in cancer area, following confirmation contract signed on Mar. 6.  Full Article

Search Stocks